

# Mesenchymal Stem Cells (MSC) and Angiogenesis in Pancreatic and Prostate Cancer

B.M. Beckermann<sup>1\*</sup>, G. Kallifatidis<sup>1\*</sup>, A. Apel<sup>1</sup>, A. Groth<sup>1</sup>, T. Wenger<sup>1,2</sup>, M. Chai<sup>3</sup>, G. Schütz<sup>3</sup>, M. Schubert<sup>5</sup>, R. Saffrich<sup>5</sup>, U. Krause<sup>5</sup>, V. Eckstein<sup>5</sup>, W. Wagner<sup>5</sup>, A. Ho<sup>5</sup>, M. W. Büchler<sup>4</sup>, H. Friess<sup>4</sup>, P. Büchler<sup>4</sup>, I. Herr<sup>1,4\*</sup>


\* Equal contribution

1. Molecular OncoSurgery Group, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany, 2. Centre d'Immunologie de Marseille-Luminy, Marseille, France, 3. Department of Molecular Biology of the Cell I, German Cancer Research Center, Heidelberg, Germany, 4. Department of General Surgery, University of Heidelberg, Heidelberg, Germany, 5. Department of Medicine V, University of Heidelberg, Heidelberg, Germany

## Introduction

Homing of manipulated mesenchymal stem cells (MSCs) to glioma xenograft models has been demonstrated in recent reports. MSCs may contribute to the formation of tumour stroma and tumour blood vessels and thus may be suitable vehicles for the targeted transfer of therapeutic genes. The formation and maintenance of blood vessels in tumours is controlled to high extent by VEGF and its receptors (-RI, -RII). In parallel, the transcription factor Hypoxia-Inducible Factor-1 (HIF-1), which is activated specifically in the tumour micro-environment, is regulating the expression of VEGF and VEGF-RI. Thus, a blockade of HIF-1 and VEGF in tumour infiltrating MSCs might interfere with the homeostasis of tumour vascularisation. In this work we could stably transduce MSC with lentiviral vectors and could design functional anti-angiogenic siRNAs.

## Results



## Summary

- We could show that it is possible to stably transduce MSCs using lentiviral vectors.
- The designed siRNAs were fully functional in *in vitro* assays (ELISA and Western Blot), shown by the down regulation of VEGF and HIF-1, respectively.

## Outlook

To facilitate *in vitro* tests, the evaluation of a lentiviral plasmid carrying the siRNA together with a GFP puromycin fusion protein as selectable marker is currently in progress.

To further evaluate the siRNA function, we next test the interaction of transduced MSC and endothelial cells in a spheroid assay.

To truly test the anti-angiogenic activity, the use of transduced MSCs in a CAM-assay as primitive *in vivo* system is envisaged.

Transdifferentiation of homed MSCs into the tumour will become a focus.